```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x


FILE 'HOME' ENTERED AT 08:13:02 ON 28 JAN 2010

=> file reg


Uploading C:\Program Files\Stnexp\Queries\10593829\rce.str
```

```
chain nodes :
1  2  3  7  8  9  10  11  14  15  16  17  18  19  20  21  22  23  24  25  26
chain bonds :
1-2  1-24  2-7  3-24  7-8  7-9  9-10  10-11  10-25  14-15  14-26  15-16  15-17
15-18  18-19  19-20  20-21  20-22  21-23  25-26
exact/norm bonds :
2-7  3-24  7-8  10-11  10-25  14-15  15-16  15-17  15-18  18-19  20-22  21-23
exact bonds :
1-2  1-24  7-9  9-10  14-26  19-20  20-21  25-26


Match level :
1:CLASS  2:CLASS  3:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS  11:CLASS  14:CLASS
15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS  21:CLASS  22:CLASS
23:CLASS  24:CLASS  25:CLASS  26:CLASS
Generic attributes :
3:
Saturation             : Saturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic

Element Count :
Node 3: Limited
    C,C5
    O,O1


L10      STRUCTURE UPLOADED
```

```
=> s l10
SAMPLE SEARCH INITIATED 08:18:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      191 TO ITERATE

100.0% PROCESSED      191 ITERATIONS                                 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2991 TO     4649
PROJECTED ANSWERS:               4 TO      200

L11           4 SEA SSS SAM L10

=> s l10 full

FULL SEARCH INITIATED 08:18:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4207 TO ITERATE

100.0% PROCESSED     4207 ITERATIONS                               34 ANSWERS
SEARCH TIME: 00.00.01

L12          34 SEA SSS FUL L10

=> file caplus


=> s l12
L13          2 L12

=> d l13 1-2 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2008:1341454  CAPLUS
DOCUMENT NUMBER:          149:534508
TITLE:                    Preparation of carbohydrate-lipid analogs and their
                          use in preventing or treating viral infection
INVENTOR(S):              Henry, Stephen Micheal
PATENT ASSIGNEE(S):       Kode Biotech Ltd., N. Z.
SOURCE:                   PCT Int. Appl., 87pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     WO 2008133534        A2    20081106    WO 2008-NZ95           20080428
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
```

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

| | | | | | |
|---|---|---|---|---|---|
| AU 2008244737 | A1 | 20081106 | AU 2008-244737 | | 20080428 |
| CA 2685269 | A1 | 20081106 | CA 2008-2685269 | | 20080428 |
| PRIORITY APPLN. INFO.: | | | NZ 2007-554853 | A | 20070427 |
| | | | NZ 2007-556736 | A | 20070724 |
| | | | NZ 2008-567754 | A | 20080424 |
| | | | WO 2008-NZ95 | W | 20080428 |

OTHER SOURCE(S): MARPAT 149:534508

AB Carbohydrate-lipid analogs are prepared for their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.

IT **1075699-41-0P** **1075699-42-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbohydrate-lipid analogs and their use in preventing or treating viral infection)

RN 1075699-41-0 CAPLUS

CN 9-Octadecenoic acid (9Z)-, 1,1'-[(1R)-1-[17-[(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl)oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl] ester (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 1075699-42-1 CAPLUS
CN 9-Octadecenoic acid (9Z)-, 1,1'-[(1R)-1-[16-[(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl)oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphahexadec-1-yl]-1,2-ethanediyl] ester (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1042259 CAPLUS
DOCUMENT NUMBER: 143:339681
TITLE: Synthetic membrane anchors
INVENTOR(S): Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen; Korchagina, Elena
PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005090368 | A1 | 20050929 | WO 2005-NZ52 | 20050322 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | | |
|---|---|---|---|---|---|---|
| AU | 2005223715 | A1 | 20050929 | AU | 2005-223715 | 20050322 |
| CA | 2560781 | A1 | 20050929 | CA | 2005-2560781 | 20050322 |
| EP | 1735323 | A1 | 20061227 | EP | 2005-722123 | 20050322 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

| | | | | | | |
|---|---|---|---|---|---|---|
| CN | 1938325 | A | 20070328 | CN | 2005-80009170 | 20050322 |
| JP | 2007530532 | T | 20071101 | JP | 2007-504907 | 20050322 |
| IN | 2006DN06089 | A | 20070831 | IN | 2006-DN6089 | 20061018 |
| US | 20070197466 | A1 | 20070823 | US | 2007-593829 | 20070112 |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | NZ 2004-531866 | A | 20040322 |
| | NZ 2005-537941 | A | 20050128 |
| | WO 2005-NZ52 | W | 20050322 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:339681

AB The invention relates to synthetic mols. such as modified glycolipids that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these mols. as synthetic membrane anchors or synthetic mol. constructs to effect qual. and quant. changes in the expression of cell surface antigens. Being able to effect qual. and/or quant. changes in the surface antigens expressed by a cell has diagnostic and therapeutic value. In a first aspect the invention consists in a mol. of the structure R-S2-L for use as a synthetic membrane anchor or in the preparation of synthetic mol. constructs where: R is a chemical reactive functional group such as bis(N-hydroxysuccinimidyl), bis(4-nitrophenyl), bis(pentafluorophenyl), and bis(pentachlorophenyl); S2 is a spacer linking R to L such as -CO(CH2)3CO-, -CO(CH2)4CO-(adipate (Ad)), and -CO(CH2)5CO-; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkyllipids, including ceramide. In a second aspect, the invention consists in a synthetic mol. construct of the structure F-S1-S2-L where: F is an antigen selected from the group consisting of carbohydrates, proteins, lipids, lectins, avidins and biotin; S1-S2 is a spacer linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkyllipids, including ceramide.

IT **865529-57-3P** **865529-65-3P** **865529-69-7P**
**865529-73-3P** **865529-77-7P** **865529-81-3P**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic membrane anchors such as glycolipids that incorporate into bilayer membranes to modify expression of cell surface antigens in relation to diagnostic and therapeutic uses)

RN 865529-57-3 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-65-3 CAPLUS
CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 865529-69-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-73-3 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-77-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.







RN 865529-81-3 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





IT **865529-57-3D**, salts **865529-58-4**
**865529-59-5** **865529-60-8** **865529-65-3D**,
salts **865529-66-4** **865529-67-5**
**865529-68-6** **865529-69-7D**, salts **865529-70-0**
**865529-71-1** **865529-72-2** **865529-73-3D**,
salts **865529-74-4** **865529-75-5**
**865529-76-6** **865529-77-7D**, salts **865529-78-8**
**865529-79-9** **865529-80-2** **865529-81-3D**,
salts **865529-82-4** **865529-83-5**
**865529-84-6** **865529-85-7** **865529-85-7D**,
salts **865529-86-8** **865529-87-9**
**865529-88-0** **865529-89-1** **865529-89-1D**,
salts **865529-90-4** **865529-91-5**
**865529-92-6**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic membrane anchors such as glycolipids that incorporate into bilayer membranes to modify expression of cell surface antigens in relation to diagnostic and therapeutic uses)

RN 865529-57-3 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-58-4 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● Na

PAGE 1-B



RN 865529-59-5 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● K

PAGE 1-B



RN 865529-60-8 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-65-3 CAPLUS
CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 865529-66-4 CAPLUS

CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



RN 865529-67-5 CAPLUS

CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● K

PAGE 1-B



RN 865529-68-6 CAPLUS
CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→2)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 865529-69-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-70-0 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● Na

PAGE 1-B



RN 865529-71-1 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● K

PAGE 1-B



RN 865529-72-2 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-[α-D-galactopyranosyl-(1→3)]-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● $NH_3$





RN 865529-73-3 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-74-4 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 865529-75-5 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-76-6 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● K

PAGE 1-B



RN 865529-77-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-78-8 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-79-9 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




● K

PAGE 1-B




RN 865529-80-2 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-81-3 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 865529-82-4 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





PAGE 1-B



RN 865529-83-5 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RN 865529-84-6 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.







RN 865529-85-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.











RN 865529-85-7 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[7-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphahexadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 865529-86-8 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-

galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





● Na

RN 865529-87-9 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





PAGE 1-B



PAGE 2-A



● K

RN 865529-88-0 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→3)-O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 2-A



● $NH_3$

RN 865529-89-1 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→4)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 865529-89-1 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→4)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.









RN 865529-90-4 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→4)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





PAGE 1-B



PAGE 2-A


PAGE 2-B


RN 865529-91-5 CAPLUS
CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→4)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 2-A

● K

RN 865529-92-6 CAPLUS
CN Phosphoric acid, mono[2-[[6-[[3-[[O-6-deoxy-α-L-galactopyranosyl-(1→2)-O-β-D-galactopyranosyl-(1→3)-O-[6-deoxy-α-L-galactopyranosyl-(1→4)]-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]propyl]amino]-1,6-dioxohexyl]amino]ethyl] mono[(2R)-2,3-bis[[(9Z)-1-oxo-9-octadecenyl]oxy]propyl] ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





PAGE 1-B



PAGE 2-A

PAGE 2-B

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> e bovin nicolai/au
E1            8     BOVIN N I/AU
E2          181     BOVIN N V/AU
E3           45 --> BOVIN NICOLAI/AU
E4            1     BOVIN NICOLAI N/AU
E5           83     BOVIN NICOLAI V/AU
E6            2     BOVIN NICOLAI VLADIMIROVICH/AU
E7            4     BOVIN NIKOLAI/AU
E8            6     BOVIN NIKOLAI V/AU
E9            1     BOVIN NIKOLAI VLADIMIROVICH/AU
```

```
E10           3     BOVIN NIKOLAJ V/AU
E11           1     BOVIN NIKOLAY/AU
E12           1     BOVIN NIKOLAY V/AU

=> s e1-e9
THE ESTIMATED SEARCH COST FOR FILE 'CAPLUS' IS 20.79 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
              8 "BOVIN N I"/AU
            181 "BOVIN N V"/AU
             45 "BOVIN NICOLAI"/AU
              1 "BOVIN NICOLAI N"/AU
             83 "BOVIN NICOLAI V"/AU
              2 "BOVIN NICOLAI VLADIMIROVICH"/AU
              4 "BOVIN NIKOLAI"/AU
              6 "BOVIN NIKOLAI V"/AU
              1 "BOVIN NIKOLAI VLADIMIROVICH"/AU
L14         331 ("BOVIN N I"/AU OR "BOVIN N V"/AU OR "BOVIN NICOLAI"/AU OR "BOVI
                N NICOLAI N"/AU OR "BOVIN NICOLAI V"/AU OR "BOVIN NICOLAI VLADIM
                IROVICH"/AU OR "BOVIN NIKOLAI"/AU OR "BOVIN NIKOLAI V"/AU OR
                "BOVIN NIKOLAI VLADIMIROVICH"/AU)

=> e gilliver lissa/au
E1            4     GILLIVER K/AU
E2            1     GILLIVER L G/AU
E3            1 --> GILLIVER LISSA/AU
E4            3     GILLIVER LISSA GWYNETH/AU
E5            1     GILLIVER LOUISE/AU
E6            1     GILLIVER MERV/AU
E7            1     GILLIVER MOIRA A/AU
E8            1     GILLIVER P J/AU
E9            1     GILLIVER PETER J/AU
E10           2     GILLIVER S C/AU
E11           1     GILLIVER S F/AU
E12           5     GILLIVER STEPHEN C/AU

=> s e3-e4
              1 "GILLIVER LISSA"/AU
              3 "GILLIVER LISSA GWYNETH"/AU
L15           4 ("GILLIVER LISSA"/AU OR "GILLIVER LISSA GWYNETH"/AU)

=> e henry stephen/au
E1            1     HENRY STANLEY MICHELLE JENNEE/AU
E2            2     HENRY STEPHANIE/AU
E3           17 --> HENRY STEPHEN/AU
E4            1     HENRY STEPHEN F/AU
E5            3     HENRY STEPHEN G/AU
E6            6     HENRY STEPHEN M/AU
E7            4     HENRY STEPHEN MICHAEL/AU
E8            4     HENRY STEPHEN MICHEAL/AU
E9            4     HENRY STEPHEN P/AU
E10           1     HENRY STEPHEN PHILIP/AU
E11           5     HENRY STEVE/AU
E12           3     HENRY STEVEN/AU

=> s e3-e10

             17 "HENRY STEPHEN"/AU
              1 "HENRY STEPHEN F"/AU
              3 "HENRY STEPHEN G"/AU
              6 "HENRY STEPHEN M"/AU
```

```
             4 "HENRY STEPHEN MICHAEL"/AU
             4 "HENRY STEPHEN MICHEAL"/AU
             4 "HENRY STEPHEN P"/AU
             1 "HENRY STEPHEN PHILIP"/AU
L16         40 ("HENRY STEPHEN"/AU OR "HENRY STEPHEN F"/AU OR "HENRY STEPHEN
               G"/AU OR "HENRY STEPHEN M"/AU OR "HENRY STEPHEN MICHAEL"/AU OR
               "HENRY STEPHEN MICHEAL"/AU OR "HENRY STEPHEN P"/AU OR "HENRY
               STEPHEN PHILIP"/AU)

=> e korchagina elena/au
E1           6     KORCHAGINA E Y/AU
E2          14     KORCHAGINA E YU/AU
E3           6 --> KORCHAGINA ELENA/AU
E4          14     KORCHAGINA ELENA Y/AU
E5           3     KORCHAGINA ELENA YU/AU
E6           2     KORCHAGINA ELENA YURIEVNA/AU
E7          12     KORCHAGINA G A/AU
E8           5     KORCHAGINA G K/AU
E9           5     KORCHAGINA G P/AU
E10          8     KORCHAGINA G T/AU
E11          2     KORCHAGINA G V/AU
E12          1     KORCHAGINA GALINA T/AU

=> s e1-e6
             6 "KORCHAGINA E Y"/AU
            14 "KORCHAGINA E YU"/AU
             6 "KORCHAGINA ELENA"/AU
            14 "KORCHAGINA ELENA Y"/AU
             3 "KORCHAGINA ELENA YU"/AU
             2 "KORCHAGINA ELENA YURIEVNA"/AU
L17         45 ("KORCHAGINA E Y"/AU OR "KORCHAGINA E YU"/AU OR "KORCHAGINA ELEN
               A"/AU OR "KORCHAGINA ELENA Y"/AU OR "KORCHAGINA ELENA YU"/AU OR
               "KORCHAGINA ELENA YURIEVNA"/AU)

=> l17 or l16 or l15 or l14
L18        371 L17 OR L16 OR L15 OR L14

=> l18 and (membrane or lipid)
        875821 MEMBRANE
        369106 MEMBRANES
        975646 MEMBRANE
                  (MEMBRANE OR MEMBRANES)
        345394 LIPID
        238549 LIPIDS
        418675 LIPID
                  (LIPID OR LIPIDS)
L19         41 L18 AND (MEMBRANE OR LIPID)

=> l19 and ?phospholipid?
        148097 ?PHOSPHOLIPID?
L20          6 L19 AND ?PHOSPHOLIPID?

=> d l20 1-6 ibib abs


L20  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2009:456160  CAPLUS
DOCUMENT NUMBER:          150:417193
TITLE:                    Functional lipid constructs and method of
                          detecting reactive antibody and method of immobilizing
```

cells or multicellular structures
INVENTOR(S): **Bovin, Nicolai**; **Henry, Stephen Micheal**; Rodinov, Igor; Weinberg, Cristina-Simona
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 138pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2009048343 | A1 | 20090416 | WO 2008-NZ266 | 20081013 |

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| NZ 2007-562475 | A | 20071012 |
| NZ 2008-569024 | A | 20080606 |
| NZ 2008-569059 | A | 20080610 |
| NZ 2008-569912 | A | 20080707 |
| NZ 2008-569964 | A | 20080718 |

OTHER SOURCE(S): MARPAT 150:417193
AB The invention relates to methods for effecting qual. and quant. changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional **lipid** constructs for use in such methods. In particular, the invention relates to functional **lipid** constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemical reactive group, conjugator or fluorophore.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:335442 CAPLUS
DOCUMENT NUMBER: 150:350139
TITLE: Peptide-**lipid** constructs and their use in diagnostic and therapeutic applications
INVENTOR(S): Weinberg, Cristina-Simona; **Bovin, Nicolai**; **Henry, Stephen Micheal**
PATENT ASSIGNEE(S): N. Z.
SOURCE: PCT Int. Appl., 80pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2009035347 | A1 | 20090319 | WO 2008-NZ239 | 20080911 |

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: NZ 2007-561381 A 20070911
NZ 2007-562475 A 20071012
NZ 2008-569023 A 20080606

OTHER SOURCE(S): MARPAT 150:350139

AB Peptide-**lipid** constructs of the structure L-S-F are disclosed, where F is a peptide, S is a spacer covalently linking F to L via an oligomer of ethylene glycol, and L is a diacyl- or dialkyl-glycerolipid (including **glycerophospholipids**). The spacer ideally has 6 to 14 ethylene glycol repeats, corresponding to PEG with a mol. weight of approx. 250 to 600. Also disclosed is a method of detecting reactive antibodies in serum by contacting serum with cells modified to incorporate a peptide-**lipid** construct, where the peptide is an epitope of the antibody, and determining the degree of agglutination of the cells. In one example, the peptides comprise determinants of the Miltenberger variants of the MNSs system.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1341454 CAPLUS
DOCUMENT NUMBER: 149:534508
TITLE: Preparation of carbohydrate-**lipid** analogs and their use in preventing or treating viral infection
INVENTOR(S): **Henry, Stephen Micheal**
PATENT ASSIGNEE(S): Kode Biotech Ltd., N. Z.
SOURCE: PCT Int. Appl., 87pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008133534 | A2 | 20081106 | WO 2008-NZ95 | 20080428 |

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

| | | | | | |
|---|---|---|---|---|---|
| AU 2008244737 | A1 | 20081106 | AU 2008-244737 | | 20080428 |
| CA 2685269 | A1 | 20081106 | CA 2008-2685269 | | 20080428 |
| PRIORITY APPLN. INFO.: | | | NZ 2007-554853 | A | 20070427 |
| | | | NZ 2007-556736 | A | 20070724 |
| | | | NZ 2008-567754 | A | 20080424 |
| | | | WO 2008-NZ95 | W | 20080428 |

OTHER SOURCE(S): MARPAT 149:534508

AB Carbohydrate-**lipid** analogs are prepared for their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-**lipid** constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-**lipid** constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.

L20 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:322099 CAPLUS
DOCUMENT NUMBER: 148:326200
TITLE: Fluorescent cell markers containing fluorophore and diacyl **lipid**
INVENTOR(S): **Korchagina, Elena**; **Bovin, Nicolai**; **Henry, Stephen**
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008030115 | A2 | 20080313 | WO 2007-NZ256 | 20070906 |
| WO 2008030115 | A3 | 20080828 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2007293770 | A1 | 20080313 | AU 2007-293770 | 20070906 |
| CA 2662624 | A1 | 20080313 | CA 2007-2662624 | 20070906 |
| EP 2069460 | A2 | 20090617 | EP 2007-834859 | 20070906 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | | | | |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | NZ 2006-549742 | A | 20060906 |
| | NZ 2006-549740 | A | 20060907 |
| | WO 2007-NZ256 | W | 20070906 |

OTHER SOURCE(S): MARPAT 148:326200

AB The preparation and use of fluorescent cell markers of the structure F-S1-S2-L is described where F is a fluorophore, S1-S2 is a spacer linking F to L, and L is a diacyl **lipid**.

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1042259 CAPLUS
DOCUMENT NUMBER: 143:339681
TITLE: Synthetic **membrane** anchors
INVENTOR(S): **Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen; Korchagina, Elena**
PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005090368 | A1 | 20050929 | WO 2005-NZ52 | 20050322 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005223715 | A1 | 20050929 | AU 2005-223715 | 20050322 |
| CA 2560781 | A1 | 20050929 | CA 2005-2560781 | 20050322 |
| EP 1735323 | A1 | 20061227 | EP 2005-722123 | 20050322 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| CN 1938325 | A | 20070328 | CN 2005-80009170 | 20050322 |
| JP 2007530532 | T | 20071101 | JP 2007-504907 | 20050322 |
| IN 2006DN06089 | A | 20070831 | IN 2006-DN6089 | 20061018 |
| US 20070197466 | A1 | 20070823 | US 2007-593829 | 20070112 |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| NZ 2004-531866 | A | 20040322 | |
| NZ 2005-537941 | A | 20050128 | |
| WO 2005-NZ52 | W | 20050322 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:339681

AB The invention relates to synthetic mols. such as modified glycolipids that spontaneously and stably incorporate into **lipid** by-layers, including cell **membranes**. Particularly, although not exclusively, the invention relates to the use of these mols. as synthetic **membrane** anchors or synthetic mol. constructs to effect qual. and quant. changes in the expression of cell surface antigens. Being able to effect qual. and/or quant. changes in the surface antigens expressed by a cell has diagnostic and therapeutic value. In a first aspect the invention consists in a mol. of the structure R-S2-L for use as a synthetic **membrane** anchor or in the preparation of synthetic mol. constructs where: R is a chemical reactive functional group such as bis(N-hydroxysuccinimidyl), bis(4-nitrophenyl), bis(pentafluorophenyl), and bis(pentachlorophenyl); S2 is a spacer linking R to L such as -CO(CH2)3CO-, -CO(CH2)4CO-(adipate (Ad)), and -CO(CH2)5CO-; and L is a **lipid** selected from the group consisting of diacyl- and dialkylglycerolipids, including **glycerophospholipids**, and sphingosine derived diacyl- and dialkyllipids, including ceramide. In a second aspect, the invention consists in a synthetic mol. construct of the structure F-S1-S2-L where: F is an antigen selected from the group

consisting of carbohydrates, proteins, **lipids**, lectins, avidins and biotin; S1-S2 is a spacer linking F to L; and L is a **lipid** selected from the group consisting of diacyl- and dialkylglycerolipids, including **glycerophospholipids**, and sphingosine derived diacyl- and dialkyllipids, including ceramide.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:837267 CAPLUS

DOCUMENT NUMBER: 139:319673

TITLE: Glycolipid-inserted embryo for the preparation of an embryo modified to enhance the implantation into the endometrium

INVENTOR(S): Blake, Deborah Adella; Carter, Nicola Lewell; **Henry, Stephen Michael**

PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.

SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003087346 | A1 | 20031023 | WO 2003-NZ59 | 20030407 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| NZ 518163 | A | 20050429 | NZ 2002-518163 | 20020405 |
| CA 2481256 | A1 | 20031023 | CA 2003-2481256 | 20030407 |
| AU 2003222519 | A1 | 20031027 | AU 2003-222519 | 20030407 |
| EP 1497411 | A1 | 20050119 | EP 2003-717799 | 20030407 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| US 20060089523 | A1 | 20060427 | US 2005-510377 | 20051107 |
| PRIORITY APPLN. INFO.: | | | NZ 2002-518163 A | 20020405 |
| | | | WO 2003-NZ59 W | 20030407 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to constructs and methods used to enhance the attachment and implantation of an embryo. It is shown that modified glycolipids and glycolipid-attachment mol. constructs can be used to modify embryos, or localized to target tissues, to enhance interaction between the embryo and the target tissue, (typically the endometrium). The invention may advantageously be used to enhance implantation of embryos in the uterus, for example, in IVF treatments.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT